Revolution Medicines, Inc. Common Stock
RVMDStock
$179.18+387.81%52W
Market Cap$39.49B
P/E—
Div yield—
Beta1.41
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)70.11%
Price vs S&P 500 (4W)17.20%
VGM Score46.58
Market Capitalization$39.49B
Earnings Surprise History
Q1 26-2.29est. -1.88
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.37
4.37
4.37
4.31
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $341.79 |
About
Revolution Medicines is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The company leverages proprietary structure-based drug discovery capabilities to create small molecules that bind to unconventional RAS variant sites. Its pipeline centers on RAS(ON) Inhibitors designed for use as monotherapy or in combination with other therapeutic agents.